Marfan Syndrome: Causes, Symptoms, and Treatment
This paper provides a comprehensive overview of Marfan syndrome, a relatively common autosomal dominant genetic disorder caused by mutations in the fibrillin-1 gene. Beginning with the disorder's historical discovery in 1896, the paper examines its epidemiology, wide-ranging clinical features—including cardiovascular defects, ectopia lentis, and skeletal abnormalities—and the molecular mechanisms behind it. It also addresses the considerable diagnostic challenges posed by variable symptom expression and phenotypic overlap with other syndromes, outlines current treatment strategies, and highlights notable individuals who have lived with or died from the condition. The paper concludes by emphasizing the urgent need for improved early screening and diagnostic tools.
- Historical Background: Discovery and early documentation of Marfan syndrome
- Epidemiology: Prevalence estimates and population distribution
- Clinical Features: Physical symptoms and diagnostic complexity
- Etiology: Fibrillin-1 mutations and TGFβ pathway disruption
- Diagnosis: Diagnostic methods, challenges, and genetic testing limits
- Treatment and Lifestyle Management: Medical interventions and activity recommendations
- Notable Individuals with Marfan Syndrome: Famous people affected by or lost to the syndrome
- Summary: Public health implications and call for better screening
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper moves logically from history through etiology to clinical management, giving readers a complete picture of the disorder without unnecessary repetition.
- Specific statistics (e.g., 75% of patients develop cardiac problems, 80% of adults show detectable lens dislocation) ground abstract medical claims in concrete, memorable figures.
- The inclusion of famous individuals adds accessibility and human interest without sacrificing scientific rigor.
Key academic technique demonstrated
The paper consistently distinguishes between what is known and what remains uncertain—for example, noting that the mechanism by which excess TGFβ causes Marfan symptoms "remains unknown," and that a definitive genetic test may not be available for some time. This epistemic honesty is a hallmark of strong medical writing and prevents overstating the evidence.
Structure breakdown
The paper is organized into eight clearly delineated sections. It opens with historical context, moves through epidemiology and clinical presentation, explains the underlying molecular biology, addresses diagnostic complexity, outlines treatment, highlights notable cases, and closes with a policy-oriented summary calling for better screening. Each section builds on the previous one, creating a coherent narrative arc from discovery to public health implication.
Historical Background
In 1896, the pediatrician Dr. Antoine Bernard-Jean Marfan described the exceptionally long, slender limbs and physique of a 5-year-old girl, Gabrielle P., before the Medical Society of the Hospital of Paris (Enersen). It is unknown whether Gabrielle P. actually suffered from what is now known as Marfan syndrome, but Dr. Henricus Jacobus Marie Weve was recognized as the first person to use the term "Marfan syndrome" to describe this common genetic disorder.
In the decades leading up to Dr. Weve's use of the term in 1931, other physicians had begun to document their encounters with this disease using radiological imaging (Enersen). Drs. Henri Mery and Leon Baonneix studied Gabrielle P. anew with this new technology in 1902 and noted a misaligned spine, thoracic asymmetry, long digits, cardiovascular abnormalities, and dislocation of the ocular lens. During the same year, Dr. Achard described a patient with similar characteristics, including joint hypermobility and a pattern of family inheritance.
Epidemiology
The estimated prevalence of Marfan syndrome can range between 1:3,000 (Lavall, Schafers, Bohm, and Laufs 228), 1:5,000 (NIAMS, "What is Marfan Syndrome?"), and 1:10,000 (Dean 724). The lowest estimate, by Lavall and colleagues, assumes that a significant number of people with Marfan syndrome remain undiagnosed (228). The prevalence of this disorder does not appear to be influenced by gender or ethnicity (NIAMS, "What is Marfan Syndrome?").
Clinical Features
Marfan syndrome is an autosomal dominant genetic disorder that is in most cases transmitted from parent to offspring (NIAMS, "What Causes Marfan Syndrome?"). Therefore, one of the cardinal features of the disorder is a family history. Common physical features include exceptionally long limbs and digits, exceptional height, a high palate, eye lens dislocation, thoracic asymmetry, hyper-flexible joints, and susceptibility to cardiac deformities (Beighton 403–404). However, a definitive diagnosis is not always straightforward, since the manifestation of the disease can vary considerably between individuals. For example, only 50% of patients are predicted to suffer from a lateral curvature of the spine (scoliosis). Other symptoms can include poor muscle development, little fat tissue, hernias, and lung disease (Thurmon 243).
Adding to the difficulty of diagnosing this disorder is that many of these symptoms can appear as part of other genetically distinct syndromes (Thurmon 242). These other syndromes include contractural arachnodactyly, Marfan-like connective tissue disorder, and several diseases resulting from collagen abnormalities. Marfan-like symptoms can also emerge due to acquired medical conditions or simply by chance. For example, extreme tallness and the heart defect mitral valve prolapse occur in the general population at rates of 3% and 6%, respectively, so physicians will occasionally encounter both in the same individual in the absence of Marfan syndrome.
One of the most common features of Marfan syndrome is ectopia lentis, which occurs when the lens of the eye becomes detached at one or more locations (Thurmon 243). This results in the lens tilting into the vitreous humor and causing vision problems. It can be easily observed in approximately 50% of adult patients and is detectable in close to 80% of adults with the proper vision test.
Another common symptom involves cardiovascular defects (Massimini 633). Those of primary concern are mitral valve prolapse and aortic aneurysms. The mitral valve controls blood flow into the aorta, and if it does not function properly, blood will flow in the wrong direction. Mitral valve prolapse can be identified in some Marfan syndrome patients at birth, and in most by age 10 (Thurmon 243). Aortic aneurysms develop when the aortic vessel expands, leading to a weakening of the vessel wall and eventual rupture (dissection). Aortic aneurysms tend to develop adjacent to the heart first and then expand toward the periphery. Some patients will experience chest pain (angina) as an early sign. Aortic insufficiency is common by the time patients reach puberty, and tears can develop in women who become pregnant. Approximately 75% of Marfan syndrome patients will develop cardiac problems, which has a significant impact on life expectancy (Lavall, Schafers, Bohm, and Laufs 228–229). Most deaths due to aortic rupture occur after age 20, with an average age of 32 years (Thurmon 243); however, these statistics apply to patients who are not receiving treatment (Lavall, Schafers, Bohm, and Laufs 229). With proper treatment, patients can live as long as 60 years.
Etiology
Marfan syndrome is caused by genetic mutations in the fibrillin-1 gene, which produces a protein essential for the proper functioning of connective tissue (NIAMS, "What Causes Marfan Syndrome?"). Approximately 75% of all cases are inherited from a parent who carries the mutated gene, and that parent would also show signs of Marfan syndrome. The remaining 25% of cases result from spontaneous mutations in the fibrillin-1 gene during the formation of sperm or eggs; in these cases, the parents themselves do not have Marfan syndrome.
The fibrillin-1 gene produces a 350 kD glycoprotein that becomes an essential component of the extracellular matrix, where it polymerizes to form microfibrils (Dean 728–729). In addition to providing structural support to tissue, these microfibrils sequester proteins of the transforming growth factor β (TGFβ) family. This sequestration prevents TGFβ from being released and exerting its effects on neighboring cells. Due to mutations in the fibrillin-1 gene, however, this TGFβ "sink" is often compromised, resulting in excess TGFβ affecting cellular function in detrimental ways. Although a defective fibrillin-1 protein may cause some structural problems, it is now believed that excess TGFβ is primarily responsible for Marfan symptoms. How this occurs at the cellular level remains unknown.
Works Cited
Beighton, Peter. Inherited Disorders of the Skeleton. New York, NY: Churchill Livingstone, 1978. Print.
Dean, John C.S. "Marfan Syndrome: Clinical Diagnosis and Management." European Journal of Human Genetics, 15.7 (2007): 724–733. Web. 5 Aug. 2012.
Enersen, Ole Daniel. Antoine Bernard-Jean Marfan. WhoNamedIt.com. n.p., 1994–2012. Web. 5 Aug. 2012.
England, Ellen. "What is Dural Ectasia?" MarfanLife.org. n.p., n.d. Web. 5 Aug. 2012.
Heart & Vascular Institute, Johns Hopkins University. "Marfan Syndrome: What is the Marfan Syndrome?" HopkinsMedicine.org. Johns Hopkins University, n.d. Web. 5 Aug. 2012.
Lavall, Daniel, Hans-Joachim Schafers, Michael Bohm, and Ulrich Laufs. "Aneurysms of the Ascending Aorta." Deutsches Ärzteblatt International 109.13 (2012): 227–233. Web. 5 Aug. 2012.
Massimini, Kathy, ed. Genetic Disorders Sourcebook. 2nd ed. Detroit, MI: Omnigraphics, 2000. Print.
NIAMS (National Institute of Arthritis and Musculoskeletal and Skin Diseases). Marfan Syndrome: Questions and Answers about Marfan Syndrome. National Institutes of Health, 2012. Web. 5 Aug. 2012.
NMF (National Marfan Foundation). "About Marfan Syndrome: Diagnosis." Marfan.org. National Marfan Foundation, 2012. Web. 5 Aug. 2012.
NMF (National Marfan Foundation). "About Marfan Syndrome: Notable Individuals & Celebrities with Marfan Syndrome." Marfan.org. National Marfan Foundation, 2012. Web. 5 Aug. 2012.
Thurmon, Theodore F. A Comprehensive Primer on Medical Genetics. New York, NY: Parthenon Publishing Group, 1999. Print.
Create your account
Always verify citation format against your institution’s current style guide requirements.